Obstructive airways disorder – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 12:24:07 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Obstructive airways disorder – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effects of Umeclidinium and Vilanterol in Patients with COPD and Heart Failure https://clinicaltrials.eu/trial/study-on-the-effects-of-umeclidinium-and-vilanterol-in-patients-with-copd-and-heart-failure/ Wed, 29 Apr 2026 14:57:32 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-umeclidinium-and-vilanterol-in-patients-with-copd-and-heart-failure/ This clinical trial is focused on studying the effects of a treatment for patients with Chronic Obstructive Pulmonary Disease (COPD) and heart failure. The treatment being tested is a combination of two medications, umeclidinium bromide and vilanterol, which are delivered as an inhalation powder called Anoro Ellipta. The study will compare the effects of this treatment to a placebo. Additionally, the study involves other medications such as Ventolin, which contains salbutamol sulfate, and Flixotide, which contains fluticasone propionate.

The purpose of the study is to investigate how the treatment with umeclidinium bromide and vilanterol affects the heart’s ability to pump blood during exercise in patients with COPD. Participants will receive the treatment or a placebo and will undergo various tests to measure their heart and lung function. These tests include exercise tests and imaging techniques like MRI and echocardiography, which use sound waves to create images of the heart.

The study will take place over a period of time, during which participants will be monitored for changes in their heart and lung function. The goal is to understand if the treatment can improve the heart’s performance during physical activity and provide better management of symptoms for patients with COPD and heart failure. Participants will be closely observed to ensure their safety and to gather accurate data on the treatment’s effects.

]]>